IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer - Liang, Heng; Li, Tianqi; Fang, Xin; Xing, Zikang; Zhang, Shengnan; Shi, Lei; Li, Weirui; Guo, Leilei; Kuang, Chunxiang; Liu, Hongrui; Yang, Qing (Cancer letters, 2021)
Keywords: Animals; Antigens; Apoptosis; Cell Movement - drug effects; Cell Proliferation - drug effects; Cytochrome; Cytotoxicity; Disease Models, Animal; Enzyme Inhibitors - pharmacology; Enzymes; Gene Expression Regulation, Neoplastic - drug effects; Genomes; Humans; Hydrocarbons; Immunomodulation; Immunosuppression; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase - genetics; Kinases; Kynurenine - biosynthesis; Kynurenine pathway; Ligands; MDSCs; Metastasis; Mice; Neoplasm Invasiveness - genetics; Neoplasm Invasiveness - pathology; Organic Chemicals - pharmacology; Organic Chemicals - therapeutic use; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - pathology; Pheochromocytoma cells; Proteins; Receptors, Aryl Hydrocarbon - genetics; Signal Transduction - drug effects; T cells; Tryptophan; Tryptophan 2,3-dioxygenase; Tryptophan Oxygenase - antagonists & inhibitors; Tryptophan Oxygenase - genetics; Tumor immunosuppression; Tumor metastasis; MDSCs; Tumor immunosuppression; T cells; Kynurenine pathway; Tumor metastasis